<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>WHO adds GLP-1RAs to essential medicines list — Newsletter</title>
<style>
:root{
  --bg:#0f172a; --panel:#111827; --ink:#e5e7eb; --muted:#9ca3af; --link:#60a5fa; --btn:#1f2937; --accent:#93c5fd;
}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--ink);font:16px/1.6 system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial}
a{color:var(--link);text-decoration:none} a:hover{text-decoration:underline}
.page{max-width:920px;margin:42px auto;padding:0 16px}
.hdr{display:flex;justify-content:space-between;align-items:center;margin-bottom:16px}
.hdr .title{font-weight:700;color:#c7d2fe}
.hdr .tagline{color:var(--muted);font-size:14px}
.card{background:var(--panel);border:1px solid rgba(255,255,255,.08);border-radius:18px;padding:22px 24px;box-shadow:0 8px 30px rgba(0,0,0,.25)}
h1{margin:0 0 6px;font-size:34px;line-height:1.2}
.meta{color:var(--muted);font-size:14px;margin-bottom:10px}
ul{margin:14px 0 0 22px;padding:0}
li{margin:8px 0}
.btn{display:inline-block;background:var(--btn);color:var(--ink);border:1px solid rgba(255,255,255,.08);padding:8px 12px;border-radius:10px;margin-right:10px}
.btn:hover{background:#374151;text-decoration:none}
.footer{color:var(--muted);text-align:center;margin:28px 0}
.hero{margin:20px 0 26px}
.grid{display:grid;gap:14px}
.grid a{display:block;padding:12px 14px;border-radius:12px;background:var(--panel);border:1px solid rgba(255,255,255,.08)}
.small{font-size:14px;color:var(--muted)}
</style>
<body>
  <div class="page">
    <div class="hdr">
      <div class="title">Daily Finance Newsletter</div>
      <div class="tagline">5–7 key bullets per story</div>
    </div>
    <div class="card">
      <h1>WHO adds GLP-1RAs to essential medicines list</h1>
      <div class="meta">2025-09-08 17:59:13+00:00 UTC</div>
      <ul>
        <li>This has led analysts at GlobalData, parent company of Pharmaceutical Technology, to forecast that Saxenda will make just $135m in 2031 – down 91% from the $1.5bn sales seen at its peak in 2022.</li>
        <li>Meanwhile, Trulicity also offers only a small price reduction, being sold at $987 instead of the $1079.77 charge for Mounjaro.</li>
        <li>Generics to improve GLP-1RA accessibility The August 2025 US approval of Teva Pharmaceutical’s generic Saxenda has left Novo Nordisk’s version vulnerable to competition.</li>
        <li>However, WHO raised concerns about the costs of both semaglutide and tirzepatide, which come with a hefty price tag of between $997 and $1349 for a one-month prescription in the US, which the agency warns could complicat</li>
        <li>The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and type 2 diabetes (T2D) drugs.</li>
        <li>The United Nations (UN) agency has added the glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists to the EML following a review from the</li>
        <li>Saxenda is currently very similar in price to its more efficacious successor, semaglutide.</li>
      </ul>
      <div class="hero">
        <a class="btn" href="https://suavir600.github.io/Newsletter/articles/who-adds-glp-1ras-to-essential-medicines-list/" target="_blank" rel="noopener">Original</a> <a class="btn" href="https://finance.yahoo.com/m/bb4b1ca7-94ec-368e-9014-307f68cd1bcb/who-adds-glp-1ras-to.html" target="_blank" rel="noopener nofollow">Source</a>
        <a class="btn" href="https://twitter.com/intent/tweet?text=WHO+adds+GLP-1RAs+to+essential+medicines+list%0A%E2%80%A2+This+has+led+analysts+at+GlobalData%2C+parent+company+of+Pharmaceutical+Technology%2C+to+forecast+that+Saxenda+will+make+just+%24135m+in+2031+%E2%80%93+down+91%25+from+the+%241.5bn+sales+seen+at+its+peak+in+2022.%0A%E2%80%A2+Meanwhile%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fwho-adds-glp-1ras-to-essential-medicines-list%2F" target="_blank" rel="noopener">Share on X</a>
      </div>
    </div>
    <div class="footer">© 2025 · Built from digest_5bullets.md</div>
  </div>
</body>
</html>
